Effect of irbesartan on ACE2 expression in diabetic rat myocardium.
- Author:
Yuan-yuan HU
1
;
Jie SHEN
;
Yan ZHU
;
Jie-long TANG
;
Shuai LIU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Biphenyl Compounds; pharmacology; Diabetes Mellitus, Experimental; enzymology; Male; Myocardium; enzymology; Peptidyl-Dipeptidase A; genetics; metabolism; RNA, Messenger; genetics; metabolism; Random Allocation; Rats; Rats, Wistar; Tetrazoles; pharmacology
- From: Journal of Southern Medical University 2010;30(6):1336-1338
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect of irbesartan on angiotensin-converting enzyme 2 (ACE2) mRNA expression in diabetic rat myocardium.
METHODSThirty 8-week-old male Wistar rats were randomly divided into control group (n=7), diabetic model group (n=14) and irbesartan group (n=9). Diabetes was induced by a single intraperitoneal injection of STZ (55 mg/kg), a blood glucose>16.7 mmol/L 72 h after the injection indicated successful establishment of diabetes. Four weeks after the modeling, the rats in irbesartan group were given 50 mg/kg irbesartan. ELISA was used to measure myocardial AngII content in the rats, and myocardial ACE2 mRNA expression was determined by real-time PCR.
RESULTSMyocardial AngII level in the diabetic model group was significantly higher than that in the control group (P<0.001). Irbesartan administration significantly lowered cardiac AngII levels in the diabetic rats (P<0.001). The rats in irbesartan group showed significantly increased myocardial ACE2 mRNA expression compared with those in the control and diabetic rat groups (P<0.05).
CONCLUSIONIrbesartan can increase ACE2 mRNA expression in the myocardium, which might be one of the mechanisms underlying its effect in improving the cardiac function in diabetic rats.
